Видео ютуба по тегу Vectorized Antibody Therapy

Novel brain penetrant capsids for Parkinson’s disease gene therapy
Novel brain penetrant capsids for Parkinson’s disease gene therapy
[GEN Webinars] Towards IND: Specificity Profiling of Antibody-Based Therapies
[GEN Webinars] Towards IND: Specificity Profiling of Antibody-Based Therapies
Immunogenicity of AAV Vectors and Transgenes - Roland Herzog
Immunogenicity of AAV Vectors and Transgenes - Roland Herzog
How Bispecific Antibodies Work
How Bispecific Antibodies Work
Introducing next-generation antibodies
Introducing next-generation antibodies
One Minute Thesis | Multispecific Antibodies
One Minute Thesis | Multispecific Antibodies
Как действуют моноклональные антитела? Ритуксимаб, инфликсимаб, адалимумаб и другие.
Как действуют моноклональные антитела? Ритуксимаб, инфликсимаб, адалимумаб и другие.
Sander van Deventer, VectorY & Forbion | Pioneering gene therapy | E11
Sander van Deventer, VectorY & Forbion | Pioneering gene therapy | E11
Therapeutic antibodies | Antibodies as medicine
Therapeutic antibodies | Antibodies as medicine
Directed Evolution of Novel AAV Vectors for Clinical Gene Therapy
Directed Evolution of Novel AAV Vectors for Clinical Gene Therapy
Evolution of Antibody Drug Conjugates
Evolution of Antibody Drug Conjugates
Immunology wars: Monoclonal antibodies
Immunology wars: Monoclonal antibodies
Направленная эволюция антител с Дугом Чапником
Направленная эволюция антител с Дугом Чапником
Novel bispecific antibodies, BITESs and ADCs for neuroendocrine carcinomas
Novel bispecific antibodies, BITESs and ADCs for neuroendocrine carcinomas
Передовые решения для разработки биспецифических антител для лечения рака
Передовые решения для разработки биспецифических антител для лечения рака
Guiding Principles When Sequencing Treatments in DLBCL
Guiding Principles When Sequencing Treatments in DLBCL
The value of bispecific antibodies in FL: current perspectives & ongoing studies with these agents
The value of bispecific antibodies in FL: current perspectives & ongoing studies with these agents
FDA Approves VectorY's VTx-002 for ALS: Revolutionizing Neurodegenerative Treatment
FDA Approves VectorY's VTx-002 for ALS: Revolutionizing Neurodegenerative Treatment
AAV vector integration events and malignancy surveillance in hemophilia gene therapy recipients
AAV vector integration events and malignancy surveillance in hemophilia gene therapy recipients
Introducing…. Invitrogen Custom Antibody
Introducing…. Invitrogen Custom Antibody
Гуманизация антител и обратные мутации
Гуманизация антител и обратные мутации
Antibody ABCs: Antibody Developability
Antibody ABCs: Antibody Developability
Using antibodies and intrabodies to target pathogenic TDP-43 in ALS
Using antibodies and intrabodies to target pathogenic TDP-43 in ALS
Inebilizumab for IgG4-Related Disease: Key Takeaways from the MITIGATE Trial
Inebilizumab for IgG4-Related Disease: Key Takeaways from the MITIGATE Trial